TScan Therapeutics, Inc.

Tscan Therapeutics, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • TCRX (NGM)

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

857 399 9500 830 Winter Street, Waltham, MA 02451, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
Nasdaq • Dec 6
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire • Nov 12
TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely - Yahoo Finance
Yahoo Finance • Aug 15
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat
MarketBeat • Dec 24
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials - Investing.com
Investing.com • Nov 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has TScan Therapeutics, Inc. had layoffs?
No layoff events have been recorded for TScan Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does TScan Therapeutics, Inc. have?
TScan Therapeutics, Inc. has approximately 146 employees.
What industry is TScan Therapeutics, Inc. in?
TScan Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is TScan Therapeutics, Inc. a publicly traded company?
Yes, TScan Therapeutics, Inc. is publicly traded under the ticker symbol TCRX on the NGM. The company has a market capitalization of approximately $0.06 billion.
Where is TScan Therapeutics, Inc. headquartered?
TScan Therapeutics, Inc. is headquartered in Waltham, MA, United States at 830 Winter Street, Waltham, MA 02451, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.